Multicenter prospective cohort study to investigate efficacy, quality of life and cost-effectiveness of obinutuzumab for untreated follicular lymphoma(PEACE-FL)

Multicenter prospective cohort study to investigate efficacy, quality of life and cost-effectiveness of obinutuzumab for untreated follicular lymphoma(PEACE-FL) - PEACE-FL study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038572

Enrollment

150

Registered

2019-11-13

Start date

2019-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

follicular lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Adult patients over 20 years old at the time of enrollment (2)Patients who have been histopathological diagnosed with follicular lymphoma according to WHO classification revision 4th edition (2017) within 6 months of enrollment (3)Patients diagnosed as follicuar lymphoma grade 1, grade 2 or grade 3a by histopathology

Exclusion criteria

Exclusion criteria: Patients judged by attending physicians to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Incremental cost- effectiveness ratio, ICER	—

Secondary

Measure	Time frame
Overall survival, OS Progression free survival, PFS POD24 (Progression of disease within 24 months) Overall response rate, ORR Complete response rate, CRR Quality of life, QOL Cost	—

Countries

Japan

Contacts

Public ContactIkuyo Tsutsumi

National Hospital Organization Mito Medical Center Department of Hematology, Clinical research center

ikuyo.ota@gmail.com029-240-7711

Outcome results